Intelligent Bio Solutions Inc. Announces Reverse Stock Split




Intelligent Bio Solutions Inc. Announces Reverse Stock Split

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company’s common stock on The Nasdaq Capital Market (“Nasdaq”) will continue, on a split-adjusted basis, with the opening of the markets on December 16, 2025, under the trading symbol “INBS” and new CUSIP number 36151G709.

The reverse stock split was approved by Intelligent Bio Solutions’ stockholders at the annual meeting of the Company’s stockholders held on October 16, 2025, with the final ratio to be determined by the Company’s Board of Directors within the ratio range authorized by shareholders.

As a result of the reverse stock split, every 10 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.  In addition, proportionate adjustments will be made to outstanding equity-based awards and other equity rights, including warrants. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share. The par value of the common stock will remain unchanged at $0.01 per share after the reverse split, and the number of authorized shares of common stock will remain at 100 million shares. Immediately after the reverse stock split becomes effective, the Company will have approximately 959,533 shares of common stock issued and outstanding. The reverse split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent the reverse split results in a stockholder receiving a cash payment in lieu of a fractional share, as described above.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Forward-Looking Statements:

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact: 
Intelligent Bio Solutions Inc. 
info@ibs.inc 
LinkedIn | Twitter

Investor & Media Contact: 
Valter Pinto, Managing Director    
KCSA Strategic Communications    
PH: (212) 896-1254    
INBS@kcsa.com     

Anavar Steroid 2026: Legal Steroid Alternative, Anavar For Women Cycle, Dosage, Side Effects, Anavar Before And After Result (Anavar for Sale) Launch Alternative Anvarol By CrazyBulk




Anavar Steroid 2026: Legal Steroid Alternative, Anavar For Women Cycle, Dosage, Side Effects, Anavar Before And After Result (Anavar for Sale) Launch Alternative Anvarol By CrazyBulk

Anavar Steroid: Cycle, Dosage, Side Effects, Most Popular Legal Steroids (Before And After Anavar Result) – Anavar for women (Anavar for Sale) – Buy Alternative Anvarol From CrazyBulk

New York City,, Dec. 12, 2025 (GLOBE NEWSWIRE) —

On September 12, 2025, CrazyBulk officially introduced Anvarol, a legal alternative to Anavar, designed specifically with both women and men in mind, addressing the growing demand for safer performance-support supplements. The launch comes at a time when fitness culture continues to expand, and many women are looking for support in achieving a lean, sculpted physique without relying on synthetic anabolic steroids. Traditional Anavar (Oxandrolone) has long been associated with physique enhancement, muscle tone improvements, and strength support, but its prescription-only status and potential hormonal side effects have created barriers and safety concerns. Click Here to Visit the Official Anvarol Website

Anavar legal Alternative Anvarol was created to mirror the performance benefits commonly discussed around Anavar—such as muscle definition support, fat-metabolism assistance, and training endurance—without synthetic hormones or the legal risks tied to controlled substances. This alternative formulation is based on natural and performance-supporting ingredients aimed at promoting lean muscle retention, energy, and recovery during training phases.

For women seeking muscle tone rather than bulk, this legal version offers an accessible option while avoiding unwanted effects sometimes linked to anabolic compounds. By combining compliance with supplement regulations, natural formulation, and a fitness-focused approach, CrazyBulk’s Anavar Steroids alternative Anvarol positions itself as a modern solution for women pursuing controlled, sustainable body-shaping results.

 Today’s fitness and sports communities continue to reference Anavar Steroids for its historical role in performance enhancement. Anvarol is 100% legal and available without a prescription.

What Is Anavar?

 Anavar, medically known as Anvarol, is an anabolic steroid Alternative By CrazyBulk in the early 1960s to help patients recover strength, rebuild muscle tissue, and regain healthy body weight after illness, surgery, or trauma. It belongs to a class of synthetic hormones designed to mimic testosterone, but with a more controlled and milder performance profile compared to stronger steroids.
Over time, Anavar became widely recognized in bodybuilding and athletic discussions because it is often associated with lean muscle retention, strength improvement, and reduced fluid buildup. Unlike some anabolic steroids that may lead to rapid bulk weight gain, Anavar is typically referenced for more moderate physical changes and is commonly mentioned in the context of cutting phases, where body fat reduction and muscle definition are the main goals.
Despite its reputation for being milder, Anavar is still a controlled substance in many countries and requires a prescription for medical use. Using Anavar without medical supervision or legal authorization can carry risks, including hormonal disruption, liver strain, and cardiovascular effects.
Today, Anavar remains known for its original medical purpose and its ongoing presence in fitness discussions, often highlighted for its heritage as one of the more selectively applied anabolic compounds. See Anavar availability and pricing from CrazyBulk

How do the Anavar Steroids Work?

Anavar Alternative Anvarol by Crazybulk, works by interacting with the body’s androgen receptors—the same receptors influenced by natural testosterone. Once active in the system, it helps increase protein synthesis, which is the process the body uses to repair and build muscle tissue. This makes it useful in medical settings where patients need help rebuilding muscle after injury, illness, or physical decline.
Another key feature of Anavar is its ability to enhance nitrogen retention in the muscles. When nitrogen levels are balanced and stable, the body remains in a more favorable state for maintaining lean muscle mass. This is one reason Anavar is often discussed in cutting cycles rather than bulking cycles, as the focus is on preserving muscle rather than increasing size.

Anavar is also associated with supporting metabolism by influencing how the body uses stored energy. While individual results vary, this may contribute to a more defined or toned appearance when combined with proper nutrition and training.
Even though Anavar is considered milder than many other anabolic steroids, it is still a synthetic hormone. For that reason, it may affect natural hormonal balance and carries possible health risks. Because of this, medical supervision and legal compliance are strongly emphasized when discussing its use.

Ingredients Commonly Found in Anavar Steroid Alternatives By Crazy Bulk

Anavar alternatives are designed to mimic the results associated with Oxandrolone but rely on legal, natural, and non-synthetic ingredients. While formulas vary by brand, many legal alternatives use a combination of botanical extracts, amino acids, vitamins, and performance-supporting compounds. Below are commonly seen ingredients presented in bullet format for clarity:

• Whey Protein Isolate – Supports muscle repair and promotes lean tissue growth.
• Soy Protein Isolate – Helps maintain muscle while supporting fat reduction.
• Branched-Chain Amino Acids (BCAAs) – Assist with muscle recovery, endurance, and strength retention.
• Wild Yam Root Extract – Sometimes included for its natural precursor compounds linked to hormone support.
• Tribulus Terrestris Extract – Commonly used to support vitality, energy, and physical performance.
• Vitamin B6 – Helps with energy metabolism and protein utilization.
• L-Carnitine L-Tartrate – May assist with converting stored fat into usable energy during training.
• Zinc – Supports normal testosterone levels and muscle function.
• Magnesium – Plays a role in muscle contraction and recovery.
• CLA (Conjugated Linoleic Acid) – Often included to support fat-burning efforts and body composition goals.

These ingredients are widely recognized in the supplement industry for supporting performance, muscle definition, recovery, and metabolic activity without the controlled-substance risks linked to anabolic steroids. More about the Anvarol cutting cycle and fat burning. Visit the Official Website

The Anavar Alternative Clinically-Inspired Formula by Crazy Bulk

The concept of Anavar-inspired supplements comes from the original clinical purpose of Oxandrolone: supporting muscle preservation, strength recovery, and overall physical function during rehabilitation. Anavar was initially developed for medical use, assisting patients facing muscle loss due to trauma, illness, or prolonged inactivity. This medical foundation inspired modern supplement manufacturers to create legal alternatives that aim to reflect similar benefits—without synthetic hormones or prescription restrictions.
Clinically-inspired Anavar alternatives typically focus on muscle retention, improved metabolism, and strength support, using natural compounds instead of anabolic steroids. These formulations are centered around ingredients that may help the body preserve lean muscle while undergoing calorie deficits or intense training.
Although these legal alternatives do not replicate the pharmacological effects of Oxandrolone, their goal is to offer a safer, accessible option based on the original clinical intentions: maintaining muscle, supporting recovery, and helping users pursue improved body composition with a more responsible and regulated approach.
 

Anavar Benefits 

Anavar, known medically as Oxandrolone, has been recognized for several effects in both medical use and athletic discussions. While responses vary by individual, the benefits most commonly associated with Anavar are listed below in point format for clarity:

• Supports Lean Muscle Preservation
  Often referenced during calorie restriction or cutting phases, where maintaining muscle is a priority.
• May Assist in Strength Improvement
  Known for contributing to strength without large fluctuations in body weight.
• Low Water Retention Profile
  Commonly discussed for creating a more defined or toned look rather than bulk.
• Potential Fat Metabolism Support
  Some users report improved muscle-to-fat ratio when paired with proper nutrition and training.
• Used Medically for Muscle-Wasting Conditions
  Originally prescribed to help patients rebuild or maintain muscle after trauma or prolonged illness.
• May Help with Recovery
  Sometimes noted for aiding physical rehabilitation and tissue repair.
• Recognized for Milder Characteristics Compared to Stronger Steroids
  Often referenced as having a more controlled effect profile in regulated medical use.
• Possible Performance Enhancement
  Athletes often associate Anavar with endurance, strength, consistency, and muscle firmness.

These benefits come from both clinical history and long-standing performance discussions. Legal and responsible usage guidelines remain strongly advised.
Anavar Cycle
An Anavar cycle refers to a planned period of using Oxandrolone, typically organized with a start point, duration, and dosage pattern. In discussions around performance enhancement, Anavar cycles are often shorter than those of stronger anabolic steroids, as it is commonly referenced as a milder compound. Many users mention cycles ranging from six to eight weeks, although medical guidance and legal regulations emphasize that any use should only occur under prescription and supervision.
Anavar cycles are frequently discussed in relation to cutting phases rather than bulking, because it is commonly associated with muscle preservation, definition, and strength maintenance while lowering body fat. Some fitness users also mention pairing Anavar with structured nutrition and resistance training to maximize results.
Post-cycle support may also be discussed to help the body rebalance after synthetic hormone exposure. However, legal frameworks and health authorities warn that unregulated use carries risks, and medical oversight is strongly advised.

Anavar for Women 

The topic of Anavar for women continues to attract attention in bodybuilding, fitness, and medical discussions because Anavar is often described as one of the milder anabolic steroids. Women are sometimes drawn to it because it is commonly associated with lean muscle support, moderate strength improvement, and a more defined physique rather than excessive mass gain. This makes Anavar a frequently referenced option in conversations surrounding cutting cycles and body shaping.
In medical settings, Anavar has been used to assist women recovering from weight loss, muscle-wasting conditions, surgery, or severe trauma. However, while the compound may be seen as milder, it is still a synthetic hormone and carries potential risks. Possible side effects include voice deepening, increased body hair, menstrual disruption, and other signs of virilization, especially without medical supervision.
Because Anavar is a controlled substance in many countries, non-prescription use is illegal and may present serious health risks. For this reason, many individuals seeking similar benefits explore legal, non-hormonal alternatives designed to support muscle tone, energy, and metabolic balance without hormonal impact.
Anyone considering Anavar for women—whether for medical or performance purposes—should prioritize legal compliance, safety awareness, and guidance from a qualified professional.

Anavar for Men 

The topic of Anavar Alternative for men is widely discussed in fitness and bodybuilding communities because Anavar, or Oxandrolone, is often viewed as a milder anabolic steroid with a focus on lean muscle enhancement rather than significant size gains. Men interested in improving muscle definition, strength levels, and overall body composition often reference Anavar as a potential option during cutting cycles, where fat reduction and muscle preservation are key goals.
 Click Here to Visit the Official Anvarol Website

In medical environments, Anavar has been used to support recovery from muscle-wasting conditions, trauma, and post-surgical rehabilitation. It is appreciated for its reputation of offering strength benefits without excessive water retention, which can create a more sculpted appearance compared to bulk-focused steroids.
However, despite being considered milder, Anavar is still a synthetic hormone and may affect testosterone levels and overall endocrine balance. Potential side effects for men may include reduced natural testosterone production, cholesterol changes, and liver strain, especially when used without medical oversight.
Because Anavar is a controlled substance, non-prescription use is illegal in many regions. Many men seeking similar benefits now turn to legal supplement alternatives intended to support muscle tone, metabolic performance, and workout recovery without hormone disruption. Proper guidance and compliance remain essential when discussing Anavar for men.

Anavar Steroid Dosage 

Dosage recommendations vary depending on medical guidance, fitness goals, and individual response. In general discussions, the following points are commonly referenced:

• Medical dosage: Often lower and determined by a healthcare professional.
• Beginners: May start with conservative levels to assess tolerance.
• Men (performance use): Commonly referenced ranges are higher than women, due to hormonal differences.
• Women (performance use): Typically discussed in lower ranges to reduce virilization risk.
• Cycle duration: Often mentioned between 6–8 weeks in fitness discussions.
• Post-cycle approach: Sometimes recommended to support hormonal balance.

Anavar Steroid Side Effects

Although Anavar is often described as milder than many anabolic steroids, it can still cause side effects, especially when used without proper medical supervision. Possible effects may include hormonal disruption, reduced natural testosterone production, and changes in cholesterol levels. Some users may experience liver strain, particularly at higher doses or with long-term use. Women may face virilization symptoms such as deeper voice, facial hair, and menstrual changes. Other reported effects include mood shifts, fatigue, headaches, and decreased libido. Because Anavar is a controlled prescription drug, professional medical guidance and legal compliance are strongly recommended to reduce risks.

Anavar Before And After Result 

Before starting Anavar, many individuals focus on goals such as increased muscle definition, improved strength, or a leaner body composition. However, results can vary depending on diet, training routine, dosage, and overall health. During use, Anavar is often associated with gradual improvements rather than dramatic overnight changes. Users commonly report improved muscle tone, better workout endurance, and a tighter or more defined look, especially during cutting phases.
After completing a cycle, some individuals may notice visible differences in muscle firmness, strength levels, and fat reduction if paired with disciplined nutrition and exercise. However, results are not guaranteed, and maintaining progress may require continued training and lifestyle consistency.
It is important to note that Anavar is a prescription-controlled steroid, and non-medical use may carry health risks such as hormonal imbalance or liver strain. For many, legal non-steroidal alternatives are explored as a safer option to pursue similar goals.

How to Use Anavar Steroid Alternatives 

Anavar steroid alternatives Anvarol are typically taken as daily supplements rather than in strict steroid-style cycles. Most products recommend one to three capsules per day, usually with food to support better absorption. Consistency is important, and results are often best when paired with a structured workout routine focused on strength training and balanced nutrition. Many users follow a six-to-eight-week schedule, sometimes followed by a short break before restarting. Unlike real steroids, no post-cycle therapy is required because these formulas do not disrupt hormone levels. Always follow the manufacturer’s instructions and consult a professional if you have health concerns or medical conditions.

Who Needs Anavar? 

Anavar, or Oxandrolone, is primarily intended for individuals who require medical support to rebuild or maintain muscle following serious illness, surgery, injury, or conditions that cause muscle loss. In clinical settings, it may be prescribed to help patients regain strength, improve body weight, or support recovery. Outside the medical environment, Anavar is often discussed among athletes and bodybuilders focused on muscle definition, strength improvement, and physique refinement rather than mass gain. However, because Anavar is a controlled substance, non-prescription use is not recommended. Anyone considering it should consult a licensed medical professional to ensure legal and safe use.
Pricing, Packages & Official Website – Where to Buy the Anavar Steroids Alternatives Anvarol by CrazyBulk Safely Online?
You can browse official options and pricing for CrazyBulk’s legal alternatives on their official website (crazybulk.com). Packages and deals vary — they often offer bulk packs, combo bundles, and discounts. Always purchase directly from their official site to ensure authenticity, product safety, and valid pricing.

Tips for Best Results with Anavar for Men and Women 

To maximize results, pair Anavar use with a structured workout plan focused on resistance and strength training. Maintain a clean diet high in protein and stay hydrated. Adequate sleep
and consistency are essential for recovery and progress. Avoid exceeding recommended guidelines, and consider periodic breaks. For safety, medical supervision is strongly advised, especially regarding dosage, cycle duration, and potential side effects. Responsible use helps support better long-term results and well-being.

Why Anavar Alternative By CrazyBulk cutting cycles in Men and Women Is an Emerging Trend in 2025?

Anavar’s rising interest in 2025 is driven by growing fitness culture, increased focus on lean physiques, and discussions around performance enhancement. Both men and women are exploring Anavar because it’s often referenced as a milder steroid with a reputation for supporting strength and muscle definition. As more people pursue aesthetic goals and body sculpting, Anavar remains a trending topic in performance and physique communities.

Final Verdict — Anavar Alternative By CrazyBulk?

As a legal Steroids, over-the-counter alternative to synthetic steroids, Anavar by CrazyBulk can offer benefits for those seeking muscle maintenance, lean definition, and workout support. It avoids the hormonal risks of real steroid use. However, its effectiveness depends heavily on consistent training, nutrition, and realistic expectations. It’s best suited for people after gradual, controlled gains — not dramatic transformations.

Manufactured under the Technical Guidance of:
Project name: Crazybulk
244 Madison Avenue,
New York City, NY 10016-2817
Postal code: NY 10016-2817
Media Contact:
Full Name – Neil Bowers
Company website: https://www.crazybulk.com/
email: support@crazybulk.com
+1 888-708-6394

Advertise with us: Info@allprsolution.com

Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain




Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain

IND filing and initiation of Phase 2 clinical trials on track for 1H 2026

SAN DIEGO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies, today announced the completion of its Phase 1 clinical trial evaluating its lead product candidate, CG001419, a potential first-in-class, oral, pan-TRK protein degrader, which is part of a new class of pain signaling channel modulators for the treatment of pain.

Cullgen’s Phase 1 study (NCT06636500) was a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose/food-effect (with or without food) and multiple-ascending-dose trial that evaluated the safety, tolerability and pharmacokinetic characteristics of CG001419 in 78 healthy volunteers. The study was conducted in Australia after receiving ethics committee approval in early 2025. Results from the study showed that all doses were well-tolerated with no drug-related serious adverse events observed.

“We are very pleased with the positive outcome of this Phase 1 study. CG001419 is an important program as it could provide a new, non-opioid, non-NSAID analgesic therapy option for patients suffering from acute and chronic pain,” commented Ying Luo, Ph.D., Chief Executive Officer of Cullgen. “Given the favorable outcome of this study, we plan to submit an IND for CG001419 in early 2026, and, pending FDA allowance of the IND, initiate a Phase 2 study in acute pain in bunionectomy patients in the United States. In addition to studying CG001419 in pain applications, it is also being studied in a separate Phase 1 clinical trial in China in patients with solid tumors.”

Pipeline Update

In addition to CG001419, Cullgen continues the advancement of CG009301, a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, as well as progressing its pipeline of pre-clinical targeted protein degraders and degrader-antibody conjugates.

Cullgen recently advanced a new cell cycle protein degrader product candidate into preclinical studies and is preparing to initiate IND-enabling studies. Also, in the near future, Cullgen anticipates advancing an additional product candidate into IND-enabling studies for the treatment of inflammatory diseases.

About Cullgen Inc.

Cullgen is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies designed to improve the lives of patients suffering from critical conditions such as pain, or cancer and inflammatory diseases. Cullgen has created a portfolio of highly selective targeted protein degrader product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients. By leveraging its expertise in targeted protein degraders, Cullgen believes its product candidates have many distinct advantages over other therapeutic modalities, including higher selectivity, improved therapeutic profile and avoidance of known toxicities.

Cullgen’s lead product candidate, CG001419, is an oral pan-tropomyosin receptor kinase (“TRK”) degrader that recently completed a Phase 1 trial for the treatment of acute post-operative pain. The molecule is also being studied in a Phase 1 trial for the treatment of solid tumors. Cullgen’s second product candidate, CG009301, is a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, including relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and acute lymphoblastic leukemia. In addition to CG001419 and CG009301, Cullgen is also progressing a number of preclinical programs including next-generation degrader-antibody conjugates.

For more information, please visit www.cullgen.com.

Forward-Looking Statements

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. These forward-looking statements include express or implied statements relating to: the therapeutic potential and utility, efficacy and clinical benefits of CG001419, including for the treatment of pain and solid tumors; the risk/benefit profile of CG001419, including the potential of CG001419 to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain; expectations regarding Cullgen’s research and development efforts, including timing of Cullgen’s anticipated IND filing with the FDA and initiation of Phase 2 trials for CG001419; Cullgen’s expectations regarding the advancement of product candidates into IND-enabling studies; and Cullgen’s expectations, hopes, beliefs, intentions and strategies; and other statements that are not historical fact. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to: risks associated with the Cullgen’s ability to manage expenses and unanticipated spending and costs that could reduce Cullgen’s cash resources; risks related to the Cullgen’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability of the Cullgen to obtain sufficient additional capital to continue to advance its product candidates, its preclinical programs and its clinical trials; the ability of the Cullgen to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; Cullgen’s ability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials; Cullgen’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; Cullgen’s ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments and Cullgen’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; changes in expected or existing competition; and legislative, regulatory, political and economic developments. A discussion of these and other factors, including risks and uncertainties with respect to Cullgen, is set forth in Pulmatrix Inc.’s (“Pulmatrix”) definitive proxy statement/prospectus filed with the Securities and Exchange Commission and declared effective on May 9, 2025, as may be supplemented or amended by Pulmatrix’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as risk factors associated with companies, such as Cullgen, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or, should any of Cullgen’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Cullgen does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Pulmatrix or Cullgen.

CONTACTS:

Cullgen Inc.

Thomas Eastling, CFO

ir@cullgen.com

Investors

Chuck Padala
Managing Director, LifeSci Advisors
chuck@lifesciadvisors.com

EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint




EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint

EssilorLuxottica to acquire Signifeye,
further growing its ophthalmology clinics footprint

Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and clinics in the Flanders region.

The transaction comes soon after the recent acquisition of Optegra, a fast-growing and highly integrated ophthalmology platform in Europe operating over 70 clinics in the UK, Czech Republic, Poland, Slovakia and the Netherlands. While strengthening Optegra’s position in Europe, it also advances EssilorLuxottica’s med-tech trajectory and its ambition to pioneer the most advanced, integrated and expert-driven medical model, capable of addressing the full continuum of need, from prevention and early detection to specialized clinical management.

Offering both medically necessary ophthalmic treatments and elective vision procedures, the Signifeye platform provides the full spectrum of eye healthcare services. In line with Optegra, Signifeye has built a reputation for clinical excellence in the private sector, trusted care and industry-leading outcomes.

“With Signifeye joining EssilorLuxottica’s ecosystem, we strengthen our ability to deliver truly end-to-end eye care and redefine what medical excellence can be across the entire patient journey. By combining our medical and scientific innovation capabilities with Signifeye’s proven clinical excellence, we can meaningfully enhance the patient experience and empower people to live their best lives,” commented Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica.

“Joining forces with EssilorLuxottica and Optegra marks a transformative chapter for Signifeye. By combining their global leadership in vision care with our commitment to patient care and clinical excellence, we look forward to building the future of eye care together,” added Kathleen Moons, Chief Executive Officer at Signifeye.

The transaction is expected to close by Q1 2026.

Attachment

• DOWNLOAD THE PRESS RELEASE

EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint




EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint

EssilorLuxottica to acquire Signifeye,
further growing its ophthalmology clinics footprint

Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and clinics in the Flanders region.

The transaction comes soon after the recent acquisition of Optegra, a fast-growing and highly integrated ophthalmology platform in Europe operating over 70 clinics in the UK, Czech Republic, Poland, Slovakia and the Netherlands. While strengthening Optegra’s position in Europe, it also advances EssilorLuxottica’s med-tech trajectory and its ambition to pioneer the most advanced, integrated and expert-driven medical model, capable of addressing the full continuum of need, from prevention and early detection to specialized clinical management.

Offering both medically necessary ophthalmic treatments and elective vision procedures, the Signifeye platform provides the full spectrum of eye healthcare services. In line with Optegra, Signifeye has built a reputation for clinical excellence in the private sector, trusted care and industry-leading outcomes.

“With Signifeye joining EssilorLuxottica’s ecosystem, we strengthen our ability to deliver truly end-to-end eye care and redefine what medical excellence can be across the entire patient journey. By combining our medical and scientific innovation capabilities with Signifeye’s proven clinical excellence, we can meaningfully enhance the patient experience and empower people to live their best lives,” commented Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica.

“Joining forces with EssilorLuxottica and Optegra marks a transformative chapter for Signifeye. By combining their global leadership in vision care with our commitment to patient care and clinical excellence, we look forward to building the future of eye care together,” added Kathleen Moons, Chief Executive Officer at Signifeye.

The transaction is expected to close by Q1 2026.

Attachment

• DOWNLOAD THE PRESS RELEASE

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period




Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement

• Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
• Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029

COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained growth into the next decade and contributing to Genmab’s evolution into a biotechnology leader.

“The Merus acquisition marks a pivotal step in the delivery of Genmab’s long-term strategy and strengthens our path to becoming a global biotechnology leader with sustained growth and profitability. We are energized by the potential of petosemtamab to meaningfully impact the lives of people with head and neck cancer. Backed by our track record of successful development and commercial execution, we look forward to unlocking petosemtamab’s full potential and delivering on its promise to patients,” said Jan van de Winkel, Ph.D., President and Chief Executive Officer of Genmab.

The addition of petosemtamab, Merus’ lead asset, to Genmab’s promising late-stage pipeline is a compelling strategic fit with Genmab’s portfolio and aligns with Genmab’s expertise in antibody therapy development and commercialization in oncology. Based on this successful track record in late-stage development and excellence in commercial execution, Genmab expects to launch petosemtamab in 2027, subject to clinical results and receipt of regulatory approvals. Genmab also intends to broaden and accelerate petosemtamab’s development with potential expansion into other lines of therapy. Following the initial approval of petosemtamab, Genmab believes that petosemtamab will be accretive to EBITDA with at least one-billion-dollar annual sales potential by 2029, with multi-billion-dollar annual revenue potential thereafter.

At 5:00 p.m. New York City time on December 11, 2025 (the “Expiration Time”), the Offer and withdrawal rights expired as scheduled. The depositary for the Offer has advised Genmab and Purchaser that, as of the Expiration Time, a total of 71,463,077 of Merus’ issued and outstanding common shares, constituting 94.2% of its issued and outstanding common shares, had been validly tendered pursuant to the Offer and not properly withdrawn. Effective at 12:01 a.m. New York City time on December 12, 2025, Purchaser accepted for payment, and expects to promptly pay for, all Merus common shares validly tendered and not properly withdrawn pursuant to the Offer.

Subsequent Offering Period
Genmab also announced that, as previously disclosed, Purchaser is providing a subsequent offering period of ten business days (the “Subsequent Offering Period”), commencing today, December 12, 2025, that will expire at 5:00 p.m., New York City time on December 29, 2025. During the Subsequent Offering Period, Purchaser will offer to purchase additional common shares at the same consideration of $97.00 per share, less any applicable withholding taxes and without interest. All Common shares validly tendered during the Subsequent Offering Period will be immediately accepted and promptly paid for by Purchaser.

Following completion of the Subsequent Offering Period, Genmab and Purchaser intend to complete the acquisition of 100% of Merus through a series of previously disclosed back-end transactions. Merus shareholders who do not tender their common shares of Merus in the Offer will receive payment for their common shares following the completion of these transactions (subject to applicable withholding taxes and without interest).

About Genmab 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines^®. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

Company Announcement no. 54
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 121225_CA54_Completion of Tender Offer

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period




Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement

• Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
• Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029

COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained growth into the next decade and contributing to Genmab’s evolution into a biotechnology leader.

“The Merus acquisition marks a pivotal step in the delivery of Genmab’s long-term strategy and strengthens our path to becoming a global biotechnology leader with sustained growth and profitability. We are energized by the potential of petosemtamab to meaningfully impact the lives of people with head and neck cancer. Backed by our track record of successful development and commercial execution, we look forward to unlocking petosemtamab’s full potential and delivering on its promise to patients,” said Jan van de Winkel, Ph.D., President and Chief Executive Officer of Genmab.

The addition of petosemtamab, Merus’ lead asset, to Genmab’s promising late-stage pipeline is a compelling strategic fit with Genmab’s portfolio and aligns with Genmab’s expertise in antibody therapy development and commercialization in oncology. Based on this successful track record in late-stage development and excellence in commercial execution, Genmab expects to launch petosemtamab in 2027, subject to clinical results and receipt of regulatory approvals. Genmab also intends to broaden and accelerate petosemtamab’s development with potential expansion into other lines of therapy. Following the initial approval of petosemtamab, Genmab believes that petosemtamab will be accretive to EBITDA with at least one-billion-dollar annual sales potential by 2029, with multi-billion-dollar annual revenue potential thereafter.

At 5:00 p.m. New York City time on December 11, 2025 (the “Expiration Time”), the Offer and withdrawal rights expired as scheduled. The depositary for the Offer has advised Genmab and Purchaser that, as of the Expiration Time, a total of 71,463,077 of Merus’ issued and outstanding common shares, constituting 94.2% of its issued and outstanding common shares, had been validly tendered pursuant to the Offer and not properly withdrawn. Effective at 12:01 a.m. New York City time on December 12, 2025, Purchaser accepted for payment, and expects to promptly pay for, all Merus common shares validly tendered and not properly withdrawn pursuant to the Offer.

Subsequent Offering Period
Genmab also announced that, as previously disclosed, Purchaser is providing a subsequent offering period of ten business days (the “Subsequent Offering Period”), commencing today, December 12, 2025, that will expire at 5:00 p.m., New York City time on December 29, 2025. During the Subsequent Offering Period, Purchaser will offer to purchase additional common shares at the same consideration of $97.00 per share, less any applicable withholding taxes and without interest. All Common shares validly tendered during the Subsequent Offering Period will be immediately accepted and promptly paid for by Purchaser.

Following completion of the Subsequent Offering Period, Genmab and Purchaser intend to complete the acquisition of 100% of Merus through a series of previously disclosed back-end transactions. Merus shareholders who do not tender their common shares of Merus in the Offer will receive payment for their common shares following the completion of these transactions (subject to applicable withholding taxes and without interest).

About Genmab 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines^®. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

Company Announcement no. 54
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 121225_CA54_Completion of Tender Offer

Poppins Launches Integrated Pediatric Care Platform to Support Working Parents with Medical, Behavioral, and Coaching Services




Poppins Launches Integrated Pediatric Care Platform to Support Working Parents with Medical, Behavioral, and Coaching Services

New York, NY, Dec. 12, 2025 (GLOBE NEWSWIRE) — Poppins has announced the launch of its integrated pediatric care platform designed to support working parents with medical, behavioral, and coaching services in one coordinated experience. The platform was built in response to growing challenges facing families across the United States.

According to HHS, 48% of American parents report overwhelming daily stress, compared to just 26% of adults without children. The traditional pediatric care model often separates medical care, behavioral health, and parent support, requiring families to coordinate between disconnected providers, wait weeks for appointments, and navigate everyday concerns without clear guidance.

“I made three pediatrician appointments in 10 days for medical issues – busted chin, pink eye, flu symptoms – while also dealing with daily meltdowns over getting dressed for school and playing musical beds at night,” says Alexandria Stried, CEO & Co-founder of Poppins. “There has to be a better way: can I go somewhere to address all of this?”

Poppins CEO & Co-Founder, Alexandria Stried is on a mission to change pediatric care and parent support

Stried and Poppins President & Co-founder Jenn Schoen experienced the burnout from this fragmentation as working parents, so they decided to build an alternative: Poppins, an AI-native platform that combines pediatric medical care, behavioral health, and parent coaching in one place, so families don’t have to figure out which expert to call or whether their concerns are “serious enough” to warrant attention.

Less than a year later, Poppins is live in six states for 24/7 virtual pediatric medical care and nationwide for behavioral support, parent coaching, and sleep coaching, offering families immediate access to experts who consider the full picture of a child’s health needs.

How the Platform Works

Poppins operates on a simple premise: parents shouldn’t have to figure out which expert to call. They should just be able to text and get help.

The platform combines family services that traditionally exist separately – 24/7 virtual pediatric medical care, behavioral support, parent coaching, and sleep coaching – into one integrated experience. Built as an AI-native platform from the ground up, Poppins uses proprietary AI workflows to triage incoming concerns, surface relevant insights from past interactions, and route families to the right care team member.

When a parent reaches out through Poppins’ secure messaging platform about issues like fever, cough, or ADHD-related concerns, a pediatric expert responds in under 15 minutes. AI-enabled tools assist the clinician by highlighting the child’s history, prior interactions, and other relevant details to provide personalized support.

The care itself is delivered by pediatric nurse practitioners with backgrounds from institutions like Boston Children’s Hospital, Seattle Children’s, Children’s Hospital of Pennsylvania, and NY-Presbyterian, along with certified parent coaches and sleep consultants. The clinical team is overseen by Chief Medical Officer Dr. Mona Amin, who also sees families on the platform. The AI infrastructure allows clinicians to see more families while maintaining quality and catching symptoms connected to behavior or sleep health that might otherwise be missed.

Families use Poppins for a wide range of needs – from peer pressure and developmental milestones to rashes, frequent night wakings, family core values, screen time limits, co-parenting questions, and more.

Early Traction and What’s Working

Poppins is already serving hundreds of families with a +94 Net Promoter Score and delivering real value:

• 67% of families report reduced household stress within nine weeks.
• 70% of medical cases have been successfully resolved virtually, saving families time and money.
• When kids do need in-person care, Poppins helps families skip expensive emergency room visits 65% of the time, routing them to the right place instead of the most convenient one.

User feedback indicates fewer unnecessary ER visits, reduced out-of-pocket costs, and earlier attention to concerns like separation anxiety or sleep-related challenges.

What’s Next

Poppins currently offers 24/7 virtual pediatric medical care in Florida, New York, Pennsylvania, New Jersey, Texas, and Illinois, with behavioral support, parent coaching, and sleep coaching available nationwide.

Families can purchase memberships starting at $20 per month. The company is also preparing to introduce insurance-based pediatric medical care and is working with employers to offer Poppins as an employee benefit for working parents. The long-term goal is to make integrated pediatric and family support more accessible to families across the country.

To learn more about the service, please visit https://www.heypoppins.com/.

About Poppins

Poppins is an AI-enabled pediatrics and parenting platform delivering whole-child, family-centric care designed to meet the needs of modern families. The Company’s comprehensive digital platform integrates 24/7 virtual pediatric medical care with same-day behavioral, sleep, and parent coaching in one seamless solution. Families can access a Poppins pediatric expert in minutes through the Company’s convenient, and HIPAA-compliant text-based platform. Poppins pediatric experts provide timely guidance; virtual diagnosis, treatment, and prescriptions, as needed; and evidence-based support customized to meet the needs of each unique family.

Media Contact
Company Name: Poppins, Inc.
Contact Person: Jenn Schoen, President & Co-Founder
Contact Number: (215) 559-9353
Email: hello@heypoppins.com
Country: United States
Website: https://www.heypoppins.com
Socials: @heypoppins, @heypoppinstok

CONTACT: Media Contact
Company Name: Poppins, Inc.
Contact Person: Jenn Schoen, President & Co-Founder
Contact Number: (215) 559-9353
Email: hello@heypoppins.com
Country: United States
Website: https://www.heypoppins.com
Socials: @heypoppins, @heypoppinstok

Poppins Launches Integrated Pediatric Care Platform to Support Working Parents with Medical, Behavioral, and Coaching Services




Poppins Launches Integrated Pediatric Care Platform to Support Working Parents with Medical, Behavioral, and Coaching Services

New York, NY, Dec. 12, 2025 (GLOBE NEWSWIRE) — Poppins has announced the launch of its integrated pediatric care platform designed to support working parents with medical, behavioral, and coaching services in one coordinated experience. The platform was built in response to growing challenges facing families across the United States.

According to HHS, 48% of American parents report overwhelming daily stress, compared to just 26% of adults without children. The traditional pediatric care model often separates medical care, behavioral health, and parent support, requiring families to coordinate between disconnected providers, wait weeks for appointments, and navigate everyday concerns without clear guidance.

“I made three pediatrician appointments in 10 days for medical issues – busted chin, pink eye, flu symptoms – while also dealing with daily meltdowns over getting dressed for school and playing musical beds at night,” says Alexandria Stried, CEO & Co-founder of Poppins. “There has to be a better way: can I go somewhere to address all of this?”

Poppins CEO & Co-Founder, Alexandria Stried is on a mission to change pediatric care and parent support

Stried and Poppins President & Co-founder Jenn Schoen experienced the burnout from this fragmentation as working parents, so they decided to build an alternative: Poppins, an AI-native platform that combines pediatric medical care, behavioral health, and parent coaching in one place, so families don’t have to figure out which expert to call or whether their concerns are “serious enough” to warrant attention.

Less than a year later, Poppins is live in six states for 24/7 virtual pediatric medical care and nationwide for behavioral support, parent coaching, and sleep coaching, offering families immediate access to experts who consider the full picture of a child’s health needs.

How the Platform Works

Poppins operates on a simple premise: parents shouldn’t have to figure out which expert to call. They should just be able to text and get help.

The platform combines family services that traditionally exist separately – 24/7 virtual pediatric medical care, behavioral support, parent coaching, and sleep coaching – into one integrated experience. Built as an AI-native platform from the ground up, Poppins uses proprietary AI workflows to triage incoming concerns, surface relevant insights from past interactions, and route families to the right care team member.

When a parent reaches out through Poppins’ secure messaging platform about issues like fever, cough, or ADHD-related concerns, a pediatric expert responds in under 15 minutes. AI-enabled tools assist the clinician by highlighting the child’s history, prior interactions, and other relevant details to provide personalized support.

The care itself is delivered by pediatric nurse practitioners with backgrounds from institutions like Boston Children’s Hospital, Seattle Children’s, Children’s Hospital of Pennsylvania, and NY-Presbyterian, along with certified parent coaches and sleep consultants. The clinical team is overseen by Chief Medical Officer Dr. Mona Amin, who also sees families on the platform. The AI infrastructure allows clinicians to see more families while maintaining quality and catching symptoms connected to behavior or sleep health that might otherwise be missed.

Families use Poppins for a wide range of needs – from peer pressure and developmental milestones to rashes, frequent night wakings, family core values, screen time limits, co-parenting questions, and more.

Early Traction and What’s Working

Poppins is already serving hundreds of families with a +94 Net Promoter Score and delivering real value:

• 67% of families report reduced household stress within nine weeks.
• 70% of medical cases have been successfully resolved virtually, saving families time and money.
• When kids do need in-person care, Poppins helps families skip expensive emergency room visits 65% of the time, routing them to the right place instead of the most convenient one.

User feedback indicates fewer unnecessary ER visits, reduced out-of-pocket costs, and earlier attention to concerns like separation anxiety or sleep-related challenges.

What’s Next

Poppins currently offers 24/7 virtual pediatric medical care in Florida, New York, Pennsylvania, New Jersey, Texas, and Illinois, with behavioral support, parent coaching, and sleep coaching available nationwide.

Families can purchase memberships starting at $20 per month. The company is also preparing to introduce insurance-based pediatric medical care and is working with employers to offer Poppins as an employee benefit for working parents. The long-term goal is to make integrated pediatric and family support more accessible to families across the country.

To learn more about the service, please visit https://www.heypoppins.com/.

About Poppins

Poppins is an AI-enabled pediatrics and parenting platform delivering whole-child, family-centric care designed to meet the needs of modern families. The Company’s comprehensive digital platform integrates 24/7 virtual pediatric medical care with same-day behavioral, sleep, and parent coaching in one seamless solution. Families can access a Poppins pediatric expert in minutes through the Company’s convenient, and HIPAA-compliant text-based platform. Poppins pediatric experts provide timely guidance; virtual diagnosis, treatment, and prescriptions, as needed; and evidence-based support customized to meet the needs of each unique family.

Media Contact
Company Name: Poppins, Inc.
Contact Person: Jenn Schoen, President & Co-Founder
Contact Number: (215) 559-9353
Email: hello@heypoppins.com
Country: United States
Website: https://www.heypoppins.com
Socials: @heypoppins, @heypoppinstok

CONTACT: Media Contact
Company Name: Poppins, Inc.
Contact Person: Jenn Schoen, President & Co-Founder
Contact Number: (215) 559-9353
Email: hello@heypoppins.com
Country: United States
Website: https://www.heypoppins.com
Socials: @heypoppins, @heypoppinstok

MedSpa Marketing Partners Unveils NORA: The AI Revolution in MedSpa Client Engagement




MedSpa Marketing Partners Unveils NORA: The AI Revolution in MedSpa Client Engagement

SACRAMENTO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) — MedSpa Marketing Partners launches NORA, an AI-powered voice agent, transforming client engagement and appointment bookings for medical spas 24/7.

Introduction: A New Era in MedSpa Client Engagement

MedSpa Marketing Partners (MSMP), a leading innovator in digital marketing solutions for the medical spa industry, is excited to announce the launch of its groundbreaking AI voice agent, NORA™. This state-of-the-art technology aims to solve a long-standing problem faced by medical spas: missed opportunities due to timing mismatches between peak client interest and business hours.

Designed specifically for the med spa market, NORA™ acts as a virtual assistant capable of engaging website visitors, answering questions, and booking appointments 24/7, ensuring that potential clients never slip through the cracks again. This innovative AI technology bridges the critical gap where most med spas fall short, late-night client engagement. With NORA™, medical spas can connect with high-value clients even when their teams are off-duty.

The Challenge: Missed Opportunities Due to Timing Disconnect

The med spa industry is currently facing a significant issue: the best prospects, busy, working women with disposable income, are making decisions in the evening, after regular business hours. These potential clients often browse websites late at night, seeking information about treatments like Botox, facial rejuvenation, or body contouring. However, when these visitors are ready to take action, most med spas are closed, leaving them with few options. They may have to fill out a form and wait for a response, or leave a voicemail, only to receive a delayed response the next day.

This slow response time costs med spas significantly. Industry research estimates that missed calls and delayed follow-ups cost med spas as much as $240,000 annually. Furthermore, statistics show that 78% of customers book services with whichever practice responds first. The timing of these interactions is more critical than ever, making real-time availability the most important factor in securing new clients.

The Solution: NORA™ – An AI Voice Agent with a Human Touch

NORA™ is poised to transform the way med spas engage with their clients. The AI-driven voice agent integrates directly into a med spa’s website, responding to visitor inquiries in real-time through a seamless voice and chat interface. NORA™ is designed to converse naturally, addressing client questions about treatment options, pricing, and downtime, while also providing personalized consultations.

Unlike other robotic, stilted AI systems, NORA™ features an adaptive, conversational tone. It can engage in back-and-forth discussions, adjust to interruptions mid-sentence, and handle unexpected questions with ease. This capability makes NORA™ an exceptionally human-like assistant, improving the client experience and making it far more engaging than traditional automated systems.

Eric Sharp, founder and CEO of MedSpa Marketing Partners, shared his excitement about the new technology: “We are on the brink of something remarkable. In the next 12 to 18 months, I believe AI voice agents like NORA™ will become indistinguishable from human conversations. Med spas that adopt this technology today are positioning themselves years ahead of their competition.”

Moreover, NORA™ is fully HIPAA-compliant, ensuring that all patient data and interactions meet the strict privacy and security standards required by healthcare providers.

Comprehensive Capabilities for MedSpa Success

NORA™ is not just a chat or voice bot, it’s the centerpiece of the MedSpa AI Revenue Engine, a comprehensive platform designed to streamline and automate every aspect of client engagement. With NORA™, medical spas can:

• Engage website visitors through voice and chat 24/7
• Handle inbound and outbound calls, offering full availability
• Book appointments directly into the spa’s practice management system
• Provide answers to treatment questions and address FAQs
• Send pre-appointment reminders and post-treatment follow-ups
• Nurture leads and re-engage lapsed clients with tailored communication
• Support sales conversations that drive conversions and bookings

Beyond just answering questions, NORA™ plays a pivotal role in automating lead capture and follow-up processes. The system uses sophisticated email and SMS sequences to nurture prospects over time, ensuring they are consistently guided along their customer journey. With advanced customer segmentation, leads are categorized based on treatment interests, demographics, service preferences, and potential value, allowing for highly personalized marketing efforts.

Tailored for MedSpas: CRM and Advertising Tools Built for the Industry

MedSpa Marketing Partners has designed the MedSpa AI Revenue Engine with the unique needs of the medical spa industry in mind. Unlike generic CRMs, this system understands the nuances of aesthetic treatments, tracking everything from Botox touch-ups to complex body contouring procedures. By monitoring treatment intervals and identifying at-risk clients, the platform ensures that no customer is overlooked.

Additionally, the platform includes streamlined advertising tools, allowing med spas to easily launch ad campaigns with industry-specific templates. These tools simplify the process, making it easier for spa owners to reach their ideal clients without needing extensive marketing expertise.

Future-Proofing the MedSpa Industry

Looking ahead, Sharp predicts that the industry will soon be divided between med spas that embrace intelligent automation like NORA™ and those that struggle to keep up. “The practices that adopt AI-powered systems today will build a competitive edge for the next decade,” he said. “AI technology is not just solving an immediate issue , it’s creating the infrastructure that will support med spas for years to come.”

By adopting NORA™ now, med spas can ensure they remain competitive in a rapidly evolving market, meeting the expectations of clients who demand immediate, personalized service at all hours of the day.

About MedSpa Marketing Partners

MedSpa Marketing Partners (MSMP) is a digital marketing and technology company dedicated to helping medical spas optimize their client acquisition, engagement, and retention strategies. With a focus on leveraging innovative AI tools and automation, MSMP provides tailored solutions that empower med spa owners to grow their businesses and deliver exceptional customer experiences.

Media Contact

Eric Sharp
Founder & CEO
MedSpa Marketing Partners
Email: support@medspamarketingpartners.com
Website
Instagram
Facebook

Disclaimer:  This content is provided by MedSpa Marketing Partners. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/fb9f6080-ac0b-4d8d-a0fa-efd43e7e5b0c
https://www.globenewswire.com/NewsRoom/AttachmentNg/1428edb6-55c4-47c9-a550-54551cd96f38